Cacace Angela M 4

What Happened

• Angela M. Cacace, Chief Scientific Officer of Arvinas, was granted compensation awards on February 26, 2026: 45,000 restricted stock units (RSUs) and a derivative award covering 67,000 shares (reported as an option/derivative). The Form 4 shows an acquisition price of $0.00 for both grants (i.e., the RSUs represent contingent rights to receive shares for no consideration). These are awards/compensation grants rather than open-market purchases or sales.

Key Details

• Transaction date: February 26, 2026; Form 4 filed March 2, 2026 (timely filing).
• Reported amounts and prices: 45,000 RSUs @ $0.00; 67,000 derivative/option shares @ $0.00 (as reported on the Form 4).
• Vesting (per footnotes): RSUs vest over four years — 25% on each Feb 26 of 2027, 2028, 2029 and 2030. The option’s underlying shares vest 25% on Feb 26, 2027, then monthly in equal installments through Feb 26, 2030; all vesting is subject to continued service.
• RSU settlement: Each RSU represents a contingent right to receive one share upon settlement for no consideration (per footnote).
• Shares owned after the transaction: not specified in the provided filing excerpt.
• No indication of a 10b5-1 plan, tax withholding sale, or late filing in the provided data.

Context

• These awards are standard equity compensation for executives and do not indicate immediate buying or selling of company stock. The RSUs will convert to shares only as they vest; the option is a derivative award whose exercise terms (e.g., exercise price) are not detailed in the excerpt beyond the reported $0 acquisition entry. Such grants are typically intended for retention and compensation rather than a direct market signal.